Good morning. Uh, I'm humbled and honored to be here today representing the team at Vicentra. We're a Dutch-based insulin uh um insulin pump company um that has developed and commercialized the Kido insulin patch pump system. Um I've spent about 25 years in healthcare working with Boston Scientific Metronic Diabetes uh Saurin Group here in the in Europe and most recently at at Procept Bio Robotics uh in the urology urology space and I'm thrilled to be now part of Vicentra. I joined Vicentra about six months ago as CEO. Um we are a commercial stage company. Uh and I'd like to tell you a little bit more about the Kido insulin patch pump system. This is Kido. Kido is the smallest, the thinnest, the lightest, and the most precise insulin patch pump in its class. It's also built with premium materials that people actually want to wear versus have to wear. And that might seem counterintuitive to, you know, those in the medical device space where it's all about the performance. But when you have a chronic condition uh and you are wearing something 247 every day for the rest of your life, you don't want to be constantly reminded that you have that chronic condition. So we're commercial scale. Uh we uh have 3,500 patients on the system. Um that's from about 200 at the beginning of 2024. We're commercialized in Germany, the France, and the Netherlands. Um and honestly the only thing holding us back right now is our ability to supply enough product. So we manufacture the disposables for this system uh in our Utre Netherlands headquarters. Um and we are at capacity. So uh we actually in fact uh if speaking of uh demand we have over 800 patients in Germany alone right now that we've told it's going to take six months before we can provide you a product. They still want our product and so they've been prescribed a kido and they're waiting for that. So what do we need to do? Well, the good news is we announced last week the completion of a series D $85 million round. That was a much larger round than we had started. Um but we're not done yet. So the way that that round is structured from a term sheet perspective, we're looking to do a second close in October and are looking for one to two additional investors that may want to come in under the same terms of this first round to raise another 20 to 22 million euro. What are we using the funds for? The first off is scaling manufacturing. So we've identified and um signed contract with an Asian contract manufacturing organization. It's actually a wholly owned American company. uh we're going to outsource our disposables manufacturing to China. Uh that process has already started. So literally within 24 hours of the funds coming into the bank, I issued purchase orders for over 5 million euro in capital equipment to get that process started. If all goes well, uh that process uh we will have unconstrained supply for the first time in the company's history next spring. In addition to that, we want to take that extra supply and uh and use it to commercialize more broadly in Europe. We'll start by going deeper in the companies that in the countries that we're in today. Uh Germany is our beach head. Uh it's the second largest insulin pump company or uh country in the world. Uh and so we plan to go much deeper there and we'll be looking to double if not triple the sales team uh as we have a better understanding of uh when that supply will come on board. And then finally, our Kido 2 is virtually done with development. Uh the pilot line has been built uh at our headquarters. Uh we are moving into verification and validation testing right now. Uh and then plan to submit that for CRAK in January of 2026. use the back half of 2026 to complete additional testings for for FDA and submit to FDA in December of 2026, which would put us in the US market in 2027. Uh we have a fantastic team. We're based in Utrich, the Netherlands. Uh we have about 210 employees right now. Roughly half of that that employee base are operators uh producing the disposables. and what's most incredible with a company of 200 and so employees, we have over 31 nationalities represented in the company, which is an incredibly diverse uh and really exciting culture. I don't need to tell anybody that diabetes is a huge market. Um, it is very much underpenetrated in the insulin uh pump uh arrange arena. But what you notice is where all the growth is coming is in wearable pumps. Everybody knows about Omnipod. Uh it's all over the TV commercials in the United States. That company has grown at roughly 20% keger for the last seven years. Taking market share largely from Metronic Diabetes, which only 5 years ago had 70% market share. It's now down to about 40%. So this is our this is our uh our product offering. So, if you are a patient and you are prescribed a kido pump, you're going to receive a starter kit that comes with two um two pumps in up to 10 color choices. You get to choose your colors. Uh comes with an inserter for the infusion set, a handheld device today uh for our algorithm. Uh and then a a charger uh to be able to ch recharge those uh the pump. On the far right, these are our disposables. So, you get a topup kit uh once uh once a month. It includes 10 infusion sets, 10 insulin cartridges, and the 10 patches that are used to apply the pump to uh to the body. So, we have a very competitive system in the market today. Uh we're partnered with Diaboloop uh with their DBLG1 uh automated insulin delivery algorithm and Dexcom using the G6 uh sensor today. um that delivers roughly 70% time and range and best-in-class uh on the low glucose metrics. To put that in context, we're in the competitive zone on time and range. Uh Omnipod is typically in the mid60s. Metronic, the market leader on outcomes, is usually in the mid70s. And so we feel really good about being in that competitive zone. Uh it is the smallest and lightest, as I mentioned before. Uh it is waterproof. Uh meaning that you can shower with it, you can swim with it. Uh unlike most other patch pump systems, you can take ours on and off. So there are times where you don't want to have a pump on. Uh if you wear the Omnipod, you have to remove the whole thing. You waste all the insulin that was in that and you have to reset when you want to. Ours you can simply remove it. Uh maybe you want to go in a sauna. Uh maybe you want to go swimming. Maybe you're playing high contact sports, you want to take it off for a little bit. you can take it off and then you can quickly reapply it. But the system's going to get better. So last month we announced Cark with Diaboloop of the next generation system. This is the DBLG2 algorithm. Uh that brings a couple of really key advancements to our system. First and foremost, smartphone controlled. So we will no longer need the handheld. Patients will be able to use their smartphone uh to communicate with the device. That's a re that's a top three uh priority in terms of pain points uh for for patients. Number two, it will be integrated with the new Dexcom G7 disposable sensor. It's very small. It has a 15-day wear. And then finally, we've made improvements to the user interface as well as some algorithmic improvements uh included. So, today we offer choice. So, we have two different infusion set sites. Uh we have a 2-in version uh which simply allows you to insert pretty much anywhere on body and then attach the pump right next to it. We also have a 12-in infusion set and that's typically used in two manners. For men, they'll infuse in the abdomen and then they hold the pump in their pocket. For women, because our pump is so lightweight, uh they will infuse in the abd abdomen and tuck the pump uh into their bra and not even know it's there. But we're not done. So this is Kaleido 2. So Kido 2 does a couple of key things. The first one is from an an aesthetic perspective, we've matured the design. Uh it's got a really beautiful look and feel. It will come in six colors. Um the uh it's smaller than the Kaleido 1, which is impressive because Kaleido 1 was already the smallest available. Uh and then we have also upgraded the entire internals. So new chipset uh new hardware to allow us to futureproof this product uh and as well as bringing on new sensors. So it has an accelerometer built in for future algorithmic development as well as a temperature sensor built in. Uh and then maybe most importantly for those that uh are in the space uh it will be tubeless compatible. So we are building a tubeless infusion set which I'll talk about here in a moment which this pump when launched in Europe next year will be able to claim that it's tubless So this is how we've done the tubless design. So we have a tubless infusion set. Uh the prototype will be completed a functional prototype will be completed in uh in early winter. Uh and then we will move forward with that over the course of next year. Uh but when this launches in Europe in 2026, we will be able to claim that it is tubeless ready. That's a big deal for a patient that is buying something that's going to last for four years. I know this firsthand. My youngest daughter has type one and for the last 17 years as a father, I've had to help her make those choices in terms of which pump do you use? And so you look out into the company's future So just to give you a sense of how much smaller uh and lighter our pump is versus the competition, the three pumps on the right represent roughly 90% market share. Um our product is 30 or or the tandem moi which is just being launched in Europe right now is over 30% larger than ours, 30% heavier than ours. Uh the insulate is 37%. That's the patch pump that is most often used today. And then Metronic, which still is the market leader, uh, is five times bigger than our product. This is my daughter's 780G device. And so the Metronic is a great product. That's what she has in the US. This is our product. Our product weighs the equivalent of less than four nickels for those Americans that are in the room. The Metronic battery that's used to supply this, that isn't even included in it right now, weighs more than our pump does. Now, it's not just about size and uh and weight. It's also about the look and feel. All of these other products look like medical devices. Every day when a patient looks at their device, they're constantly reminded that they have a medical device. Ours look like a fashion Uh, and so we have lots of influencers that enjoy actually showing their pump um and and being proud of it and and so it does create a different look and feel and since this is such a direct to consumer market today unlike 10 years ago I it makes a big difference. Now what allows us to have that small size uh and the and the precision accuracy on the pumping it's really our unique pumping mechanism. So unlike traditional infusion pumps that use a reservoir and a syringed driven pump system, we use a valve system uh which has two one-way valves that allow us to deliver micro doses much much smaller than the competition at precise accuracy. And don't just trust me uh about that information. We've had uh a third party go out and test all of the insulin pumps that are on the market and you can see the kido system in terms of accuracy at low dosing is vastly superior to others that are on the market. Our main competition Omnipod has the widest variation in the space. So what is how about our commercial traction? So in Germany we've uh commissioned some market research. This looks at about 50 users and where did they come from? Roughly 50% of our users are coming from multiple daily injections. So they're using pens today uh which is normal in the space. But the other 45% or so are coming from the competition. And we feel really good that roughly 25% are coming from Omnipod, 25% are coming from Metronic. Those are the market leaders today and we're competing with them right now. As I mentioned, uh we are very quickly going to be moving to an outsourced supplier in Asia. Uh that transfer has started this week. Uh and uh by the end of uh next May June, we will have unconstrained supply for the first time in the country company's history. And the uh the CMO that we've selected also gives us flexibility from a tariff perspective. So, as we move to the US, should there be Asian tariffs in place, we have the ability to transfer additional lines to manufacturing sites in the US, Mexico, or Costa Rica. Quickly, on the revenue side, uh we're going to do about 12 million euro in revenue today with about 4,000 patients by the end of the year. Next year, when that supply comes on board, the back half of the year is really, really strong. uh particularly in Germany, we believe we'll be around 12,000 patients by the end of next year, an exit quarter Q4 run rate of close to 40 million euro uh and on our way uh to 100 million euro in in a short amount of time. We will enter the US at the end of 2027. There's not a lot of US n uh patients in these numbers and so the US growth for the most part is all upside to what I'm showing you here. US strategy, it's simple. um the the the diabetes space uh has interoperable uh capability and so we have a simple 510k submission. There's several predicates that are already in place uh that we can follow. Uh most importantly, it does not require another clinical uh and Diaboloop, our algorithm supplier has already submitted for their FDA approval and it's uh pending right So, last but not least, we feel really good about our our product today. We feel great about the product that's coming and about our future. Uh, and if you're interested in being part of a second close sometime in mid to late October, uh, please reach out to me. I'd love to talk to you. Um, and, uh, thank